MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

This real-world study suggests that MET overexpression, as assessed by IHC, is associated with better survival in advanced NSCLC patients treated with ICIs, independent of PD-L1 level. These results suggest the potential of MET expression as a predictive marker for ICI efficacy in advanced NSCLC patients and support the combination of MET-targeted agents with anti-PD1/PD-L1 ICIs as a promising strategy for NSCLC patients with MET overexpression.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-11-27
DOI
https://doi.org/10.3390/cancers17233801
Primary Topic
Liver physiology and pathology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

Haniel Alves Araújo, Jia Wu, Xiuning Le, Wei Lü et al.
Cancers
Liver physiology and pathology
article

MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

Haniel Alves Araújo, Jia Wu, Xiuning Le, Wei Lü, Frank V. Fossella, Don L. Gibbons, Khaja Khan, Bingnan Zhang, Marcelo Vailati Negrao, Elliana Young, Ignacio I. Wistuba, Lingzhi Hong, Waree Rinsurongkawong, Mehmet Altan, Pedro Rocha, John Victor Heymach, Ferdinandos Skoulidis, Ara Asadur Vaporciyan, Hai T. Tran, Anne S. Tsao, Carl M. Gay, Tina Cascone, Lauren A. Byers, Yasir Y. Elamin, George R. Blumenschein, Luisa M. Solis Soto, Natalie I. Vokes, Jianling Zhou, Claudio A. Arrechedera, Jianjun Zhang, J. Jack Lee, Hui Li, Rafael Bach
article en

Abstract

This real-world study suggests that MET overexpression, as assessed by IHC, is associated with better survival in advanced NSCLC patients treated with ICIs, independent of PD-L1 level. These results suggest the potential of MET expression as a predictive marker for ICI efficacy in advanced NSCLC patients and support the combination of MET-targeted agents with anti-PD1/PD-L1 ICIs as a promising strategy for NSCLC patients with MET overexpression.

CancersVol. 17(23)
The University of Texas MD Anderson Cancer Center (US), Hospital Del Mar (ES)
Openalex Percentile: Top 52%
Liver physiology and pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.